Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
M834 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| M834 | BIOLOGICAL | - |
| US-Sourced Orencia® | BIOLOGICAL | - |
| EU-Sourced Orencia® | BIOLOGICAL | - |
M834 is an investigational monoclonal antibody being developed by Johnson & Johnson (JNJ). It is currently in Phase 1 clinical development, studied in healthy volunteers. M834 is not approved and remains under investigation.
M834 is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. The drug is being studied for its pharmacokinetics and safety in healthy subjects.
M834 is being developed by Johnson & Johnson, a pharmaceutical company traded on the New York Stock Exchange under the ticker JNJ. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics.
M834 is in Phase 1 clinical development. A Phase 1 trial has been completed, involving 243 healthy volunteers. The drug is investigational and has not received regulatory approval.
M834 has one completed Phase 1 trial, identified as NCT02923583, titled "Assessment of Pharmacokinetics (PK) and Safety of M834 and Orencia ®, in Healthy Subjects." The trial enrolled 243 participants and was not randomized or double-blinded.
M834 is not the same as Orencia. The clinical trial NCT02923583 compared M834 with Orencia (abatacept) to assess pharmacokinetics and safety, indicating they are distinct drugs being evaluated in the same study.